• Home
  • About
  • Drug Development Pipeline
  • News
  • Investors
  • Careers
  • Contact
  • TSX.V: RKV
  • FSE: 7JO0
  • OTCMKTS: RKVTF

Rakovina Therapeutics Granted DTC Eligibility to Expand U.S. Investor Access

by Rakovina Therapeutics | Jul 15, 2025 | Uncategorized

DOWNLOAD Vancouver, British Columbia, July 15, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery,...

Rakovina Therapeutics Congratulates Partner – Variational Al for Winning Life Sciences BC’s 2025 Emerging Biotech Company of the Year Award

by Rakovina Therapeutics | Jul 11, 2025 | Uncategorized

DOWNLOAD Award Recognition underscores the importance of Al-driven drug discovery Vancouver, British Columbia, July 11, 2025 — Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation...

Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in Al-Enabled Oncology Drug Development

by Rakovina Therapeutics | Jul 10, 2025 | Uncategorized

DOWNLOAD Vancouver, British Columbia, July 10, 2025 — Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered...

Rakovina Therapeutics Highlights Strong H1 Progress and Unveils Strategic Priorities for H2 2025

by Rakovina Therapeutics | Jul 1, 2025 | Uncategorized

Download Vancouver, British Columbia, June 30, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery,...

Rakovina Therapeutics Announces Intention to Amend Debentures and Warrants

by Rakovina Therapeutics | Jul 1, 2025 | Uncategorized

Download Vancouver, British Columbia, June 30, 2025  – Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”) announces that it will apply to the TSX Venture Exchange (the “Exchange”) to amend the terms of certain outstanding warrants and convertible...
« Older Entries
Next Entries »

Suite 720, 999 West Broadway, Vancouver, British Columbia
Canada V5Z 1K5

Home

About

Drug Development Pipeline

News

Investors

Careers

Contact

Company Disclosure

Privacy Policy

Subscribe

To Receive Company Updates

Copyright ©2020-2026 Rakovina Therapeutics Inc. All rights reserved.  | Privacy Policy | Terms of Use |  Site by Vanooms Media